AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

LFWD · NASDAQ · Medical - Devices

Lifeward

Powered exoskeletons and anti-gravity treadmills for mobility and rehabilitation.

$7.47

After-hours close+0.01 (+0.13%)

At close$7.46(+1.29%)

Something off on this page? Send us feedback.

Profile

Lifeward Ltd.LFWDHealth Care

Develops ReWalk personal exoskeletons and AlterG Anti-Gravity Treadmills, generating primarily equipment revenue plus related service, support, and rentals; its U.S. exoskeleton business depends on payer coverage, approvals, and collection timing.

Develops powered mobility and rehabilitation devices, centered on the ReWalk Personal Exoskeleton for people with spinal-cord injuries and AlterG Anti-Gravity Treadmills for rehabilitation clinics, hospitals, and sports organizations. The portfolio also includes MyoCycle functional-electrical-stimulation bikes and the ReStore gait-training exosuit; newly acquired upper-body exoskeleton technology and an oral protein-delivery platform remain in development.

Revenue is principally equipment sales, complemented by AlterG service and support and ReWalk rentals that can lead to sales in Germany. Direct sales cover the United States and Germany while distributors serve other markets. ReWalk economics depend on payer coverage, approvals, collection timing, clinical training, and regulatory authorizations; AlterG shipments depend on manufacturing and inventory availability.

Company facts

CEOWilliam Mark Grant

ListedSep 12, 2014

ExchangeNASDAQ

HeadquartersMarlborough, MA

CountryIsrael

Employees81

CIK0001607962

ISINIL0011331076

Key statistics

Market cap$12.0M

EPS (ttm)−$16.82

P/E (ttm)−0.4435

ROE-310.9%

P/B1.71

P/S0.5507

Dividend yield—

Beta1.15vs XLV −0.02

Year to date −0.3% · Average volume (30d) 6.3K

Analysts

Price target, next 12 months$10.00+34.0%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy4 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $7.46

High$10.00+34.0%

Median$10.00+34.0%

Low$10.00+34.0%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 21, 2026	H.C. Wainwright	Reiterate	Buy	$13	$10

Earnings

EPS

Estimate−$0.79

ReportedDue Nov 13, 2026

Revenue

Estimate$7.2M

ReportedDue Nov 13, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 14, 2026Q2 FY26	−$1.39	−$1.46	−5.0%	$6.5M	$6.6M	+1.4%	−5.70%
May 15, 2026Q1 FY26	−$0.34	−$6.70	−1,870.6%	$5.8M	$3.9M	−32.1%	−1.79%
Mar 18, 2026Q4 FY25	−$0.84	−$3.60	−328.6%	$7.9M	$5.1M	−35.4%	+1.49%
Nov 14, 2025Q3 FY25	−$0.09	−$0.20	−122.2%	$7.9M	$6.2M	−21.3%	−0.56%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$5.0M	$5.7M	$6.2M	$5.1M	$3.9M	$6.6M
Gross profit	$2.1M	$2.5M	$2.7M	$1.1M	$1.3M	$2.7M
Operating income	−$4.9M	−$6.6M	−$3.1M	−$5.1M	−$10.3M	−$4.2M
Net income	−$4.8M	−$6.6M	−$3.2M	−$5.3M	−$10.8M	−$11.5M
Diluted EPS	−$5.52	−$6.96	−$2.40	−$3.60	−$6.70	−$4.12
Gross margin	42.2%	43.9%	43.7%	21.4%	34.2%	40.9%
Operating margin	-96.4%	-114.7%	-50.7%	-100.7%	-263.5%	-62.7%

Fiscal years (4-quarter sums)FY22 $5.5M · FY23 $13.9M · FY24 $25.7M · FY25 $22.0M

Revenue by product · Q2 FY26

Product$5.4M · 100%

Revenue by geography · Q2 FY26

United States$4.1M · 61%

Germany$1.1M · 17%

Europe$1.1M · 16%

Asia Pacific$235.0K · 4%

Rest Of World$138.0K · 2%

Balance sheet, Jun 30, 2026Cash & short-term investments $9.4M · Total debt $2.6M · Total assets $35.0M · Shareholders' equity $12.2M

Dividends

No dividends on record.

Ownership

Institutions 0.87%14.1K sharesInsiders 7.65%123.2K sharesOther 91.48%1.47M shares

Shares outstanding 1.61M · Float 1.56M · 96.7% free float

A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Oramed Pharmaceuticals Inc. · 10 percent owner	1.25M	77.61%	Form 4	May 14, 2026
Avraham Gabay · director	13.6K	0.85%	Form 4	Aug 24, 2026
Moshe H. Rozenbaum · director	11.5K	0.71%	Form 4	Apr 13, 2026
William Mark Sigsbee · director	11.5K	0.71%	Form 4	Apr 13, 2026
Renaissance Technologies LLC	11.4K	0.71%	13F	May 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Sep 2, 2025	Jeannine Lynch	officer: VP of Market Access & Strategy	−1,591	$0.6400